- Home
- ELVN vs IGIC Comparison
ELVN vs IGIC Comparison
Compare ELVN & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- IGIC
- Stock Information
- Founded
- ELVN 2016
- IGIC 2001
- Country
- ELVN United States
- IGIC Jordan
- Employees
- ELVN N/A
- IGIC N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- IGIC Property-Casualty Insurers
- Sector
- ELVN Health Care
- IGIC Finance
- Exchange
- ELVN Nasdaq
- IGIC Nasdaq
- Market Cap
- ELVN 1.1B
- IGIC 1.0B
- IPO Year
- ELVN 2020
- IGIC N/A
- Fundamental
- Price
- ELVN $21.47
- IGIC $23.98
- Analyst Decision
- ELVN Strong Buy
- IGIC Buy
- Analyst Count
- ELVN 5
- IGIC 3
- Target Price
- ELVN $37.80
- IGIC $23.67
- AVG Volume (30 Days)
- ELVN 246.0K
- IGIC 93.2K
- Earning Date
- ELVN 03-13-2025
- IGIC 03-11-2025
- Dividend Yield
- ELVN N/A
- IGIC 2.40%
- EPS Growth
- ELVN N/A
- IGIC 32.83
- EPS
- ELVN N/A
- IGIC 3.04
- Revenue
- ELVN N/A
- IGIC $506,160,000.00
- Revenue This Year
- ELVN N/A
- IGIC N/A
- Revenue Next Year
- ELVN N/A
- IGIC $6.64
- P/E Ratio
- ELVN N/A
- IGIC $7.88
- Revenue Growth
- ELVN N/A
- IGIC 10.67
- 52 Week Low
- ELVN $10.90
- IGIC $11.51
- 52 Week High
- ELVN $30.03
- IGIC $27.00
- Technical
- Relative Strength Index (RSI)
- ELVN 42.14
- IGIC 48.91
- Support Level
- ELVN $20.16
- IGIC $22.97
- Resistance Level
- ELVN $23.08
- IGIC $24.83
- Average True Range (ATR)
- ELVN 1.60
- IGIC 0.69
- MACD
- ELVN -0.09
- IGIC 0.04
- Stochastic Oscillator
- ELVN 25.14
- IGIC 54.30
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.